Skip to main content

Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.

Publication ,  Journal Article
Montanari, S; Jansen, R; Schranner, D; Kastenmüller, G; Arnold, M; Janiri, D; Sani, G; Bhattacharyya, S; Mahmoudian Dehkordi, S; Dunlop, BW ...
Published in: Transl Psychiatry
February 23, 2025

Acylcarnitines (ACs) are involved in bioenergetics processes that may play a role in the pathophysiology of depression. Previous genomic evidence identified four ACs potentially linked to depression risk. We carried forward these ACs and tested the association of their circulating levels with Major Depressive Disorder (MDD) diagnosis, overall depression severity and specific symptom profiles. The sample from the Netherlands Study of Depression and Anxiety included participants with current (n = 1035) or remitted (n = 739) MDD and healthy controls (n = 800). Plasma levels of four ACs (short-chain: acetylcarnitine C2 and propionylcarnitine C3; medium-chain: octanoylcarnitine C8 and decanoylcarnitine C10) were measured. Overall depression severity as well as atypical/energy-related (AES), anhedonic and melancholic symptom profiles were derived from the Inventory of Depressive Symptomatology. As compared to healthy controls, subjects with current or remitted MDD presented similarly lower mean C2 levels (Cohen's d = 0.2, p ≤ 1e-4). Higher overall depression severity was significantly associated with higher C3 levels (ß = 0.06, SE = 0.02, p = 1.21e-3). No associations were found for C8 and C10. Focusing on symptom profiles, only higher AES scores were linked to lower C2 (ß = -0.05, SE = 0.02, p = 1.85e-2) and higher C3 (ß = 0.08, SE = 0.02, p = 3.41e-5) levels. Results were confirmed in analyses pooling data with an additional internal replication sample from the same subjects measured at 6-year follow-up (totaling 4141 observations). Small alterations in levels of short-chain acylcarnitine levels were related to the presence and severity of depression, especially for symptoms reflecting altered energy homeostasis. Cellular metabolic dysfunctions may represent a key pathway in depression pathophysiology potentially accessible through AC metabolism.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Transl Psychiatry

DOI

EISSN

2158-3188

Publication Date

February 23, 2025

Volume

15

Issue

1

Start / End Page

65

Location

United States

Related Subject Headings

  • Severity of Illness Index
  • Netherlands
  • Middle Aged
  • Male
  • Humans
  • Female
  • Depressive Disorder, Major
  • Cohort Studies
  • Case-Control Studies
  • Carnitine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Montanari, S., Jansen, R., Schranner, D., Kastenmüller, G., Arnold, M., Janiri, D., … Milaneschi, Y. (2025). Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort. Transl Psychiatry, 15(1), 65. https://doi.org/10.1038/s41398-025-03274-x
Montanari, Silvia, Rick Jansen, Daniela Schranner, Gabi Kastenmüller, Matthias Arnold, Delfina Janiri, Gabriele Sani, et al. “Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.Transl Psychiatry 15, no. 1 (February 23, 2025): 65. https://doi.org/10.1038/s41398-025-03274-x.
Montanari S, Jansen R, Schranner D, Kastenmüller G, Arnold M, Janiri D, et al. Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort. Transl Psychiatry. 2025 Feb 23;15(1):65.
Montanari, Silvia, et al. “Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.Transl Psychiatry, vol. 15, no. 1, Feb. 2025, p. 65. Pubmed, doi:10.1038/s41398-025-03274-x.
Montanari S, Jansen R, Schranner D, Kastenmüller G, Arnold M, Janiri D, Sani G, Bhattacharyya S, Mahmoudian Dehkordi S, Dunlop BW, Rush AJ, Penninx BWHJ, Kaddurah-Daouk R, Milaneschi Y. Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort. Transl Psychiatry. 2025 Feb 23;15(1):65.

Published In

Transl Psychiatry

DOI

EISSN

2158-3188

Publication Date

February 23, 2025

Volume

15

Issue

1

Start / End Page

65

Location

United States

Related Subject Headings

  • Severity of Illness Index
  • Netherlands
  • Middle Aged
  • Male
  • Humans
  • Female
  • Depressive Disorder, Major
  • Cohort Studies
  • Case-Control Studies
  • Carnitine